Telomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic Dysphonia

About this update from Telomir Pharmaceuticals, Inc.

MIAMI, FLORIDA / ACCESS Newswire / May 7, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir"), a leader in age-reversal science, today announced new preclinical data showing that its lead oral drug candidate, Telomir-1, reverses multiple hallmarks of cellular decline across several human cell lines. The findings include improved mitochondrial activity, reduced oxidative stress, restored calcium balance, and protection from toxic metal effects-offering a mechanistic foundation for the Company's new research initiatives in autism spectrum disorder (ASD) and spasmodic dysphonia (SD). The in vitro studies, conducted in collaboration with SmartAssays, demonstrated Telomir-1's ability to: "This is a strong demonstration of Telomir-1's ability to restore core cell functions under conditions that mimic aging and stress," said Erez Aminov, CEO of Telomir. "These biological improvements give us confidence to pursue exploratory models in autism and spasmodic dysphonia, where these same cellular disruptions are widely documented and involved in disease initiation or progression." Scientific Rationale for Expanding into Autism and Spasmodic Dysphonia The cellular mechanisms targeted by Telomir-1-oxidative stress, mitochondrial dysfunction, calcium imbalance, and metal-induced toxicity-have been demonstrated in proliferating cells and may be directly relevant to both autism and spasmodic dysphonia (SD). "What's compelling is that Telomir-1 isn't just addressing one pathway-it's restoring balance, particularly in dividing cells, across multiple core stress systems that overlap with what has been reported in autism and SD," said Dr. Angel, Chief Scientific Advisor. "That's the foundation for our next stage of research." Regulatory Strategy and Rare Disease Development To support its rare disease pipeline, Telomir plans to participate in the FDA's Rare Disease Endpoint Advancement (RDEA) Pilot Program, which enables early regulatory dialogue on trial endpoints for underserved conditions. This initiative will support further development of Telomir-1 in rare diseases such as: About Telomir Pharmaceuticals, Inc. Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) is a pre-clinical stage pharmaceutical company seeking to lead development in several areas, including age-reversal science. Telomir is focused on the development of Telomir-1, a novel small molecule metal ion regulator designed to lengthen the DNA's protective telomere caps, which are crucial in the aging process. Telomir's goal is to explore the potential of Telomir-1, starting with ongoing research in animals and then in humans. Telomeres are the protective end caps of a chromosome made up of DNA sequences and proteins. As humans age, telomeres shorten, with metal reactivity accelerating the process, which presents humans and pet animals with an increased chance of contracting a number of degenerative and age-related diseases. Telomir's goal is to develop and gain regulatory approval for Telomir-1, proposed to be dosed orally, with the broader aim of promoting longevity and enhancing overall quality of life. Telomir-1 is in preclinical development and has not yet been tested in humans. There is no assurance that Telomir-1 will proceed through development or will ultimately receive FDA approval for marketing. Cautionary Note Regarding Forward-Looking Statements This press release, statements of Telomir Pharmaceuticals' management or advisors related thereto, and the statements contained in the news story linked in this release contain "forward-looking statements," which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1. Any forward-looking statements in this press release are based on Telomir's current expectations, estimates and projections only as of the date of this release. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications and safety of Telomir-1. These and other risks concerning Telomir's programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is on file with the SEC. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact Information Helga Moya [email protected] (786) 396-6723 SOURCE: Telomir Pharmaceuticals, Inc. View the original press release on ACCESS Newswire

View stock analysis, news, and events for Telomir Pharmaceuticals, Inc.